博瑞医药(688166.SH)部分产品拟中选国家药品接续采购

Core Viewpoint - The company, Borui Pharmaceutical (688166.SH), announced that its wholly-owned subsidiary, Borui Pharmaceutical (Suzhou) Co., Ltd., participated in the continuation procurement of drugs whose agreements have expired, with four products, including Agachuban injection, proposed for selection in the upcoming procurement [1] Group 1 - The proposed selected products for continuation procurement include four drugs, with a total sales revenue of 88.8475 million yuan in the first three quarters of 2025, accounting for 10.16% of the company's total revenue during the same period [1] - Medical institutions will prioritize the use of the selected drugs during the procurement cycle, ensuring the completion of the agreed purchase volume [1] - If contracts are signed and implemented, it will further expand the sales volume, increase market share, and enhance the company's brand image [1]